Back to matchesWe found a matchYour institution may have access to this item. Find your institution then sign in to continue.TitleFirst-in-class BTK inhibitor Imbruvica gets CLL approval.AbstractThe article discusses U.S. Food & Drug Administration's approval for Bruton tyrosine kinase (BTK) inhibitor Imbruvica (ibrutinib) for the treatment of chronic lymphocytic leukemia (CLL) as of September 2014.SubjectsPROTEIN-tyrosine kinase inhibitors; CHRONIC lymphocytic leukemia treatment; UNITED States. Food &; Drug AdministrationPublicationNature Biotechnology, 2014, Vol 32, Issue 9, p852ISSN1087-0156Publication typeArticleDOI10.1038/nbt0914-852a